Watch IGC. Know when insiders buy.
One email the day a filing lands. Free.
IGC
IGC Pharma, Inc.
0.27
+0.00 +0.00%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
65
PASS · shorts 65
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $27.9MP/E —DIV YIELD —FCF YIELD -21.25%REV TTM $1.1M −15.4%NET INCOME −$7.9MNET CASH $200K52W 0.24 – 0.42SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $265K | −19.2% | 18.1% | −$2.8M | −$2.9M | — | -0.03 | −$1.4M | $5K | −$1.4M | Aug 14 |
| Q1 2026 · Mar 31 | $317K | −3.9% | 17.4% | −$2.5M | −$2.4M | — | -0.02 | −$1.2M | $1K | −$1.2M | May 15 |
| Q4 2025 · Dec 31derived | $350K | +36.2% | 12.6% | −$2.9M | −$726K | — | -0.01 | −$1.2M | $12K | −$1.2M | Mar 18 |
| Q3 2025 · Sep 30 | $191K | −53.6% | 51.8% | −$2.9M | −$1.8M | — | -0.02 | −$2.1M | $29K | −$2.1M | Nov 14 |
| Q2 2025 · Jun 30 | $328K | +20.6% | 47.0% | −$1.9M | −$1.6M | — | -0.02 | −$1.4M | $8K | −$1.4M | Aug 14 |
| Q1 2025 · Mar 31 | $330K | +11.9% | 46.7% | −$1.4M | −$1.2M | — | -0.02 | −$730K | $18K | −$748K | May 15 |
| Q4 2024 · Dec 31 | $257K | +26.0% | 40.5% | −$1.9M | −$1.8M | — | -0.02 | −$1.3M | $27K | −$1.3M | Mar 18 |
| Q3 2024 · Sep 30 | $412K | +41.6% | 48.1% | −$1.8M | −$1.7M | — | -0.02 | −$996K | $29K | −$1M | Nov 14 |
| Q2 2024 · Jun 30 | $272K | — | 59.9% | −$2.4M | −$2.4M | — | -0.03 | −$1.8M | $38K | −$1.8M | Aug 14 |
| Q1 2024 · Mar 31derived | $295K | — | 58.0% | −$2.2M | −$2.9M | — | -0.04 | −$526K | $15K | −$541K | Jun 27 |
| Q4 2023 · Dec 31 | $204K | — | 65.2% | −$3M | −$5.6M | — | -0.09 | −$1.6M | $68K | −$1.7M | Feb 14 |
| Q3 2023 · Sep 30 | $291K | — | 59.8% | −$2.5M | −$2.5M | — | -0.05 | −$1.6M | $35K | −$1.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Mar 31 | $1.3M | 48.7% | −$7.4M | −$7.1M | -560.3% | -0.09 | −$4.8M | $112K | −$4.9M | — | — |
| FY2024 · to Mar 31 | $1.3M | 54.5% | −$9.8M | −$13M | -966.5% | -0.22 | −$5.2M | $138K | −$5.3M | — | — |
| FY2023 · to Mar 31 | $911K | 48.5% | −$11.6M | −$11.5M | -1263.0% | — | −$7M | $310K | −$7.4M | — | — |
| FY2022 · to Mar 31 | $397K | 48.9% | −$15.4M | −$15M | -3782.4% | — | −$7.5M | $236K | −$7.7M | — | — |
| FY2021 · to Mar 31 | $898K | 12.6% | −$8.7M | −$8.8M | -981.2% | -0.21 | −$10.8M | $1.5M | −$12.3M | — | — |
| FY2020 · to Mar 31 | $4.1M | 2.8% | −$6.9M | −$7.3M | -179.6% | -0.19 | −$8.7M | $4.4M | −$13.1M | — | — |
Every number comes from IGC Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.